Anemia
Aranesp "145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
Published in Blood Weekly, May 10th, 2007
Amgen (NASDAQ: AMGN) today announced the results of the "145 study", a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of Aranesp(R) (darbepoetin alfa) in 600 previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving platinum-containing chemotherapy. The study demonstrated no statistically significant difference in risk of death (overall survival Aranesp compared to placebo Hazard Ratio (HR): 0.93, 95% CI: 0.78 to 1.11) or investigator determined progression-free survival (HR: 1.02, 95% CI: 0.86 to 1.21).
The study demonstrated a significant change in hemoglobin concentration from baseline in favor of Aranesp (a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-05-10)
More Articles from Blood Weekly
- Gene Therapy
New treatment for fungus which causes thrush and sepsis - Anemia
Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease - Anemia
Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment - Cancer
Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential to Accelerate Recovery of Bone Marrow Stem Cells Following Cancer Radiation Therapy - Leukemia
Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting -Targeted Cancer Therapy Demonstrates Potent Single Agent Activity and Synergy with Other Drugs- - Leukemia
Novel Drug Preventing Protein Recycling Shows Potential for Treating Leukemia - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
